Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

Pediatric Rheumatology

Volumn 14, Issue 1, 2016, Pages

  Verazza, Sara ^a   Davì, Sergio ^b   Consolaro, Alessandro ^a,b   Bovis, Francesca ^b   Insalaco, Antonella ^c   Magni Manzoni, Silvia ^c   Nicolai, Rebecca ^c   Marafon, Denise Pires ^c   De Benedetti, Fabrizio ^c   Gerloni, Valeria ^d   Pontikaki, Irene ^d   Rovelli, Francesca ^d   Cimaz, Rolando ^e   Marino, Achille ^e   Zulian, Francesco ^f   Martini, Giorgia ^f   Pastore, Serena ^g   Sandrin, Chiara ^g   Corona, Fabrizia ^h   Torcoletti, Marta ^h   Conti, Giovanni ⁱ   Fede, Claudia ⁱ   Barone, Patrizia ^j   Cattalini, Marco ^k   Cortis, Elisabetta ^l   Breda, Luciana ^m   Olivieri, Alma Nunzia ⁿ   Civino, Adele ^o   Podda, Rosanna ^p   Rigante, Donato ^q   La Torre, Francesco ^r   D'Angelo, Gianfranco ^s   Jorini, Mauro ^t   Gallizzi, Romina ^u   Maggio, Maria Cristina ^v   Consolini, Rita ^w   De Fanti, Alessandro ^x   Muratore, Valentina ^y   Alpigiani, Maria Giannina ^b   Ruperto, Nicolino ^b   Martini, Alberto ^a,b   Ravelli, Angelo ^a,b   more..

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^h FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

ⁱ UNIVERSITY OF MESSINA   (Italy)

^j UNIVERSITY OF CATANIA   (Italy)

^k UNIVERSITY OF BRESCIA   (Italy)

^l Ospedale di Orvieto   (Italy)

^m UNIVERSITY OF CHIETI   (Italy)

ⁿ SECOND UNIVERSITY OF NAPLES   (Italy)

^o Azienda Ospedaliera Card G Panico   (Italy)

^p Osp Regionale per le Microcitemie   (Italy)

^q FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^r Ospedale A Perrino   (Italy)

^s UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^t Ospedale Pediatrico G Salesi   (Italy)

^u UNIVERSITY OF MESSINA   (Italy)

^v Ospedale dei Bambini G Di Cristina   (Italy)

^w UNIVERSITY OF PISA   (Italy)

^x S MARIA NUOVA HOSPITAL   (Italy)

^y FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

more..

Author keywords

Biologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors

Indexed keywords

ABATACEPT; ADALIMUMAB; ANAKINRA; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TOCILIZUMAB; ANTIRHEUMATIC AGENT;

ABDOMINAL PAIN; ABORTION; ACUTE PANCREATITIS; ANAL CONDYLOMATOSIS; ANGIONEUROTIC EDEMA; ANUS DISEASE; ARTICLE; AUTOIMMUNE THYROIDITIS; BEHAVIOR DISORDER; BLADDER CARCINOMA; BRONCHITIS; CELLULITIS; CERVICAL LYMPHADENOPATHY; CHICKENPOX; CHILD; CONCENTRATION LOSS; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGIC DISEASE; HEPATITIS; HERPES LABIALIS; HERPES ZOSTER; HUMAN; HYPERTRANSAMINASEMIA; HYPOCOMPLEMENTEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFLAMMATORY BOWEL DISEASE; INJECTION SITE PAIN; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METRORRHAGIA; MOOD DISORDER; MORNING STIFFNESS; NAUSEA; NEPHROLITHIASIS; NERVE PARALYSIS; NEURITIS; OSTEOMYELITIS; PAIN; PAPILLEDEMA; PERITONITIS; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RECURRENT INFECTION; REMISSION; RETROSPECTIVE STUDY; SEPSIS; STREPTOCOCCUS INFECTION; THYROID CARCINOMA; TIC; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; UVEITIS; VASCULITIS; VOMITING; ADOLESCENT; ARTHRITIS, JUVENILE; CLINICAL TRIAL; DRUG SUBSTITUTION; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG SUBSTITUTION; ETANERCEPT; FEMALE; HUMANS; MALE; METHOTREXATE; PATIENT OUTCOME ASSESSMENT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85006810814     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/s12969-016-0126-0     Document Type: Article

References (56)

1. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342:763-9.
2. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093-101.
3. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63:1638-44.
4. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60:2794-804.
5. Southwood TR, Foster HE, Davidson JE, Hyrich KL, Cotter CB, Wedderburn LR, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford). 2011;50:189-95.
6. Halbig M, Horneff G. Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Rheumatol Int. 2009;30:229-38.
7. Prince FH, Geerdink LM, Borsboom GJ, Twilt M, van Rossum MA, Hoppenreijs EP, et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2010;69:138-42.
8. Klotsche J, Minden K, Thon A, Ganser G, Urban A, Horneff G. Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept. Arthritis Care Res (Hoboken). 2014;66:253-62.
9. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2010;62:3259-64.
10. Billiau AD, Loop M, Le PQ, Berthet F, Philippet P, Kasran A, et al. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology (Oxford). 2010;49:1550-8.
11. Nielsen S, Ruperto N, Gerloni V, Simonini G, Cortis E, Lepore L, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2008;26:688-92.
12. Solari N, Palmisani E, Consolaro A, Pistorio A, Viola S, Buoncompagni A, et al. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2013;40:192-200.
13. Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford). 2011;50:214-21.
14. Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011;306:2340-7.
15. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390-2.
16. Ravelli A, Viola S, Ruperto N, Corsi B, Ballardini G, Martini A. Correlation between conventional disease activity measures in juvenile chronic arthritis. Ann Rheum Dis. 1997;56:197-200.
17. Filocamo G, Davi S, Pistorio A, Bertamino M, Ruperto N, Lattanzi B, et al. Evaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. J Rheumatol. 2010;37:1534-41.
18. Viola S, Felici E, Magni-Manzoni S, Pistorio A, Buoncompagni A, Ruperto N, et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:2092-102.
19. Filocamo G, Consolaro A, Schiappapietra B, Dalpra S, Lattanzi B, Magni-Manzoni S, et al. A new approach to clinical care of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimensional Assessment Report. J Rheumatol. 2011;38:938-53.
20. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63:929-36.
21. Magni-Manzoni S, Ruperto N, Pistorio A, Sala E, Solari N, Palmisani E, et al. Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2008;59:1120-7.
22. Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C, et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum. 2012;64:2366-74.
23. Consolaro A, Ruperto N, Bracciolini G, Frisina A, Gallo MC, Pistorio A, et al. Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. Ann Rheum Dis. 2014;73:1380-3.
24. Consolaro A, Negro G, Gallo MC, Bracciolini G, Ferrari C, Schiappapietra B, et al. Defining criteria for disease activity states in non-systemic juvenile idiopathic arthritis based on a three-variable Juvenile Arthritis Disease Activity Score. Arthritis Care Res (Hoboken). 2014;66:1703-9.
25. Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2005;32:935-42.
26. Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68:635-41.
27. Tynjala P, Vahasalo P, Honkanen V, Lahdenne P. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68:552-7.
28. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201:1479-86.
29. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol. 1998;25:203-7.
30. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin S-L, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58:1496-504.
31. Lomholt JJ, Thastum M, Herlin T. Pain experience in children with juvenile idiopathic arthritis treated with anti-TNF agents compared to non-biologic standard treatment. Pediatr Rheumatol Online J. 2013;11:21.
32. Consolaro A, Ravelli A. Paediatric rheumatology: Juvenile idiopathic arthritis--are biologic agents effective for pain? Nat Rev Rheumatol. 2013;9:447-8.
33. Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006;54:1987-94.
34. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68:519-25.
35. Wang F, Wang NS. Etanercept therapy-associated acute uveitis: a case report and literature review. Clin Exp Rheumatol. 2009;27:838-9.
36. Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res. 2010;35:751-6.
37. Calandra S, Gallo MC, Consolaro A, Pistorio A, Lattanzi B, Bovis F, et al. Female sex and oligoarthritis category are not risk factors for uveitis in italian children with juvenile idiopathic arthritis. J Rheumatol. 2014;41:1416-25.
38. Klotsche J, Niewerth M, Haas JP, Huppertz HI, Zink A, Horneff G, et al. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis. 2016;75:855-61.
39. Papadopoulou C, Kostik M, Bohm M, Nieto-Gonzalez JC, Gonzalez-Fernandez MI, Pistorio A, et al. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. J Pediatr. 2013;163:879-84.
40. Kostik MM, Gaidar EV, Hynnes AY, Dubko MF, Masalova VV, Snegireva LS, et al. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use. Clin Exp Rheumatol. 2016;34:714-8.
41. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmol. 2014;121:785-96.
42. Davies R, Southwood TR, Kearsley-Fleet L, Lunt M, Hyrich KL. Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Arthritis Rheumatol. 2015;67:2487-94.
43. Beukelman T, Xie F, Baddley JW, Chen L, Delzell E, Grijalva CG, et al. Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum. 2013;65:1384-9.
44. Renaud C, Ovetchkine P, Bortolozzi P, Saint-Cyr C, Tapiero B. Fatal group A Streptococcus purpura fulminans in a child receiving TNF-alpha blocker. Eur J Pediatr. 2011;170:657-60.
45. van Dijkhuizen EH, Pouw JN, Scheuern A, Hugle B, Hardt S, Ganser G, et al. Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: a cross-sectional, observational study. Clin Exp Rheumatol. 2016;34:148-54.
46. Wiegering V, Morbach H, Dick A, Girschick HJ. Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature. Rheumatol Int. 2010;30:801-4.
47. van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2011;38:1441-6.
48. Dallocchio A, Canioni D, Ruemmele F, Duquesne A, Scoazec JY, Bouvier R, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology (Oxford). 2010;49:1694-8.
49. Tse SML, Petty RE. Enthesitis related arthritis. In: Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, editors. Textbook of pediatric rheumatology. 7th ed. Philadelphia: Elsevier; 2016. p. 238-55.
50. Diak P, Siegel J, La GL, Choi L, Lemery S, McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010;62:2517-24.
51. Ruperto N, Martini A. Juvenile idiopathic arthritis and malignancy. Rheumatology (Oxford). 2014;53:968-74.
52. Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64:1263-71.
53. Simard J, Neovius M, Hagelberg S, Askling J. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum. 2010;62:3776-82.
54. Horneff G, Foeldvari I, Minden K, Moebius D, Hospach T. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford). 2011;50:230-6.
55. Ruperto N, Martini A. International research networks in pediatric rheumatology: the PRINTO perspective. Curr Opin Rheumatol. 2004;16(5):566-70.
56. Consolaro A, Morgan EM, Giancane G, Rosina S, Lanni S, Ravelli A. Information technology in pediatric rheumatology. Clin Exp Rheumatol. 2016;34 Suppl 101:S11-6.